Diabetologia (2019) 62:549–552
https://doi.org/10.1007/s00125-018-4795-8

CORRECTION

Correction to: Nuts as a replacement for carbohydrates in the diabetic diet: a reanalysis of a randomised controlled trial

David J. A. Jenkins[1,2,3,4,5] · Cyril W. C. Kendall[1,3,6] · Benoît Lamarche[7] · Monica S. Banach[3] · Korbua Srichaikul[1,3,8] · Edward Vidgen[1,3] · Sandy Mitchell[3] · Tina Parker[3] · Stephanie Nishi[1,3] · Balachandran Bashyam[1,3] · Russell J. de Souza[1,3,9] · Christopher Ireland[3] · Sathish C. Pichika[1,3,10] · Joseph Beyene[9] · John L. Sievenpiper[1,3,4,5] · Robert G. Josse[1,2,3,4,5]

Published online: 8 January 2019

Correction to: Diabetologia
https://doi.org/10.1007/s00125-018-4628-9

In contrast to statements made in the above paper, measurements of waist and hip circumference were in fact available. Table 2 (Biochemistry and anthropometric measurements at baseline and study end) and Table 3 (Treatment differences in change for blood and anthropometric measurements in the intention-to-treat analysis) are updated here to include the missing data for waist circumference, hip circumference and waist/hip ratio. Analysis of the data did not show any significant effects of the full-dose nut diet, full-dose muffin diet or the half-dose nut diet on waist circumference, hip circumference or waist/hip ratio within groups or between groups.

The online version of the original article can be found at https://doi.org/10.1007/s00125-018-4628-9

✉ David J. A. Jenkins
david.jenkins@utoronto.ca

[1] Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, 5th Floor, Medical Science Building (MSB), 1 Kings College Circle, Toronto, ON M5S 1A8, Canada

[2] Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, Canada

[3] Clinical Nutrition and Risk Factor Modification Centre, St Michael's Hospital, Toronto, ON, Canada

[4] Division of Endocrinology and Metabolism, St Michael's Hospital, Toronto, ON, Canada

[5] Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto, ON, Canada

[6] College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada

[7] School of Nutrition, Institute of Nutrition and Functional Foods, Laval University, Quebec City, QC, Canada

[8] Division of Family and Community Medicine, St Michael's Hospital, Toronto, ON, Canada

[9] Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada

[10] Department of Mathematics and Statistics, University of Windsor, Windsor, ON, Canada

Table 2 Biochemistry and anthropometric measurements at baseline and study end

Variable	Baseline			Study end		
	Full-dose nut diet ($n = 40$)	Half-dose nut diet ($n = 38$)	Full-dose muffin diet ($n = 39$)	Full-dose nut diet ($n = 39$)	Half-dose nut diet ($n = 32$)	Full-dose muffin diet ($n = 32$)
Glucose, mmol/l[a]	7.17 (1.48)	6.95 (1.22)	7.33 (2.17)	7.20 (1.80)	6.55 (2.90)	7.20 (1.75)
HbA_{1c}, mmol/mol[a]	52.6 (7.5)	52.3 (7.3)	53.7 (6.6)	50.8 (9.8)	50.3 (7.7)	52.4 (9.8)
HbA_{1c}, %[a]	6.97 (0.68)	6.93 (0.67)	7.07 (0.60)	6.80 (0.90)	6.75 (0.70)	6.95 (0.90)
Total cholesterol, mmol/l[a]	4.10 (1.81)	3.98 (0.93)	4.27 (1.42)	3.96 (1.21)	3.93 (1.06)	4.20 (1.42)
LDL-c, mmol/l[b]	2.46 (1.05)	2.18 (0.60)	2.29 (0.78)	2.27 (1.00)	2.04 (0.61)	2.37 (0.84)
HDL-c, mmol/l[a]	1.12 (0.35)	1.10 (0.31)	1.11 (0.35)	1.23 (0.31)	1.16 (0.34)	1.18 (0.27)
Triacylglycerols, mmol/l[a]	1.43 (0.93)	1.32 (0.64)	1.40 (0.71)	1.35 (1.08)	1.45 (0.93)	1.42 (0.93)
Total cholesterol:HDL-c ratio[a]	3.79 (1.46)	3.39 (0.81)	3.44 (1.39)	3.44 (1.36)	3.27 (1.32)	3.49 (1.69)
LDL-c:HDL-c ratio[a]	1.96 (1.31)	1.86 (0.81)	1.81 (1.27)	1.77 (1.01)	1.73 (1.04)	1.97 (1.28)
Non-HDL-c, mmol/l[a]	3.18 (1.54)	2.78 (0.87)	2.91 (1.47)	3.03 (1.17)	2.73 (1.12)	3.11 (1.55)
Triacylglycerol:HDL-c ratio[a]	1.24 (1.31)	1.11 (0.91)	1.26 (1.15)	1.06 (1.35)	1.29 (1.05)	1.28 (1.05)
ApoA1, g/l[a]	1.43 (0.24)	1.44 (0.37)	1.43 (0.22)	1.43 (0.30)	1.48 (0.35)	1.46 (0.23)
ApoB, g/l[a]	0.84 (0.36)	0.73 (0.21)	0.75 (0.26)	0.78 (0.29)	0.74 (0.24)	0.78 (0.30)
ApoB:ApoA1[a]	0.57 (0.20)	0.50 (0.23)	0.50 (0.25)	0.52 (0.21)	0.44 (0.25)	0.52 (0.28)
CRP, nmol/l[a]	1.04 (1.20)	0.87 (1.69)	1.23 (1.50)	0.86 (1.52)	1.01 (1.73)	0.92 (1.67)
Weight, kg[b]	80.0 (14.7)	86.2 (15.6)	82.9 (14.7)	79.1 (14.0)	84.8 (15.1)	82.6 (14.9)
BMI, kg/m^2 [b]	28.8 (4.5)	30.3 (5.0)	29.4 (4.2)	28.5 (4.4)	29.9 (5.2)	29.2 (4.1)
Waist (cm)[b]	102 (11)	106 (13)	106 (11)	101 (12)	105 (14)	104 (10)
Hip (cm)[b]	108 (8)	111 (10)	109 (9)	108 (8)	110 (10)	109 (9)
Waist/hip ratio[b]	0.95 (0.06)	0.96 (0.05)	0.97 (0.06)	0.94 (0.06)	0.95 (0.06)	0.96 (0.05)
Blood pressure, mmHg						
Systolic[b]	122 (11)	124 (13)	125 (13)	120 (13)	124 (15)	123 (12)
Diastolic[b]	70 (9)	72 (8)	72 (10)	69 (10)	72 (6)	72 (10)
LDL-c < 255 Å, mmol/l[a]	1.37 (0.81)	1.28 (0.84)	1.13 (0.80)	1.26 (0.73)	1.14 (0.63)	1.33 (0.90)
LDL-c 255–260 Å, mmol/l[a]	0.50 (0.68)	0.55 (0.36)	0.67 (0.57)	0.49 (0.64)	0.51 (0.37)	0.66 (0.34)
LDL-c > 255 Å, mmol/l[a]	0.20 (0.34)	0.30 (0.20)	0.31 (0.48)	0.19 (0.35)	0.27 (0.21)	0.32 (0.37)
Fibrinogen, μmol/l[b]	10.2 (1.3)	10.0 (1.9)	9.4 (1.5)	10.1 (2.0)	9.7 (1.8)	9.0 (1.8)
Factor VII, U/ml[b]	1.15 (0.25)	1.02 (0.28)	1.10 (0.21)	1.13 (0.26)	1.03 (0.23)	1.13 (0.21)
Factor VIII, U/ml[b]	1.08 (0.31)	1.20 (0.38)	1.17 (0.39)	1.20 (0.37)	1.32 (0.46)	1.33 (0.43)
PAI-1, pmol/l[a]	438 (434)	470 (227)	475 (438)	392 (215)	496 (368)	404 (381)
Antioxidants	($n = 38$)	($n = 32$)	($n = 31$)	($n = 38$)	($n = 32$)	($n = 30$)
Protein thiols (μmol/l)[b]	317.0 (71.8)	326.6 (72.2)	317.7 (53.8)	355.7 (76.3)	345.9 (6.4)	356.5 (88.7)
Conjugated dienes (μmol/l)[b]	25.2 (9.8)	22.6 (9.8)	24.2 (7.7)	23.0 (9.7)	22.1 (10.0)	21.8 (6.9)
TBARS (μmol/l)[b]	0.32 (0.10)	0.35 (0.12)	0.31 (0.10)	0.32 (0.10)	0.36 (0.12)	0.29 (0.11)

[a] Data are presented as median (interquartile range) for non-normally distributed data

[b] Data are presented as mean (SD) for normally distributed data

For baseline: HbA_{1c}, glucose and blood pressure baseline values were calculated as the mean of values at screening and weeks −1 and 0; for weight, BMI, waist circumference, hip circumference, waist/hip ratio and antioxidants, values at week 0 were used; for lipids, lipoproteins and CRP, the mean of weeks −1 and 0 were used ($n = 93$), or screening and week 0 if week −1 was missing ($n = 17$). For $n = 6$, only week 0 data were available. Data were not available for $n = 1$ who was randomised to the half-dose nut group but dropped out prior to week 0; for particle size and clotting factors, week 0 was used ($n = 113$) or week −1 if week 0 had insufficient serum quantities or samples were missing ($n = 4$)

For study end: HbA_{1c}, glucose and blood pressure study end values were calculated as the mean of weeks 8, 10 and 12 (final month); for lipid, lipoproteins and CRP, week 8, 10 and 12 samples were also used apart from for $n = 3$ who only had week 8 samples available; for weight, BMI, waist circumference, hip circumference and waist/hip ratio, week 12 values were used ($n = 100$) or, if not available, week 8 values ($n = 3$); for particle size and clotting factors, owing to limited sample availability, week 12 samples were used ($n = 97$) or, if not available, week 10 samples ($n = 3$), or week 8 samples ($n = 3$; where week 10 samples were also unavailable); for antioxidants, week 12 samples were used where serum samples were available (conjugates dienes and TBARS, $n = 100$; protein thiols, $n = 99$ [analytical failure lead to loss of data for $n = 1$ sample])

TBARS, thiobarbituric acid reactive substances

Table 3 Treatment differences in change for blood and anthropometric measurements in the intention-to-treat analysis

	Full-dose nut vs full-dose muffin diet					Full-dose nut vs half-dose nut diet					Half-dose nut vs full-dose muffin diet				
	β	95% CI	*p*	Adj CI	Adj *p*	β	95% CI	*p*	Adj CI	Adj *p*	β	95% CI	*p*	Adj CI	Adj *p*
Glucose (mmol/l)[a]	−0.02	(−0.09, 0.06)	0.610	(−0.11, 0.07)	0.867	−0.05	(−0.12, 0.03)	0.228	(−0.14, 0.04)	0.449	0.03	(−0.05, 0.10)	0.506	(−0.07, 0.12)	0.784
HbA_{1c} (mmol/mol)[b]	−2.0	(−3.8, −0.3)	0.026	(−4.2, 0.1)	0.066	−1.8	(−3.6, −0.04)	0.045	(−4.0, 0.3)	0.111	−0.2	(−2.1, 1.6)	0.813	(−2.5, 2.0)	0.969
HbA_{1c} (mmol/mol)[a]	−0.04	(−0.07, −0.01)	0.017	(−0.08, −0.001)	0.043	−0.03	(−0.07, −0.002)	0.038	(−0.07, 0.01)	0.095	−0.01	(−0.04, 0.03)	0.749	(−0.05, 0.04)	0.945
HbA_{1c} (%)[b]	−0.19	(−0.35, −0.02)	0.026	(−0.38, 0.01)	0.066	−0.17	(−0.33, −0.004)	0.045	(−0.36, 0.03)	0.111	−0.02	(−0.19, 0.15)	0.813	(−0.23, 0.18)	0.969
HbA_{1c} (%)[a]	−0.03	(−0.05, −0.005)	0.018	(−0.06, −0.0002)	0.048	−0.02	(−0.05, −0.001)	0.039	(−0.05, 0.003)	0.097	0.00	(−0.03, 0.02)	0.768	(−0.03, 0.03)	0.953
Total cholesterol (mmol/l)[a]	−0.06	(−0.12, −0.01)	0.026	(−0.13, 0.003)	0.066	−0.04	(−0.10, 0.01)	0.119	(−0.11, 0.02)	0.264	−0.02	(−0.08, 0.04)	0.508	(−0.09, 0.05)	0.785
LDL-c (mmol/L)[a]	−0.09	(−0.18, −0.0004)	0.049	(−0.20, 0.02)	0.120	−0.04	(−0.13, 0.05)	0.383	(−0.15, 0.07)	0.657	−0.05	(−0.15, 0.04)	0.288	(−0.17, 0.06)	0.537
Small LDL-c (<255 Å, mmol/l)[a,c,d]	−0.35	(−0.61, −0.10)	0.007	(−0.66, −0.05)	0.018	−0.07	(−0.32, 0.19)	0.601	(−0.37, 0.24)	0.860	−0.29	(−0.55, −0.02)	0.034	(−0.60, 0.03)	0.085
Medium LDL-c (255-260 Å, mmol/l)[a,c,d]	0.10	(−0.13, 0.33)	0.382	(−0.17, 0.38)	0.655	0.00	(−0.23, 0.24)	0.976	(−0.27, 0.28)	1.000	0.10	(−0.14, 0.34)	0.417	(−0.19, 0.38)	0.694
Large LDL-c (>255 Å, mmol/l)[a,c,d]	−0.08	(−0.52, 0.37)	0.732	(−0.61, 0.46)	0.937	0.18	(−0.27, 0.62)	0.433	(−0.36, 0.71)	0.711	−0.25	(−0.70, 0.19)	0.264	(−0.79, 0.28)	0.502
HDL-c (mmol/l)	0.00	(−0.05, 0.05)	0.987	(−0.06, 0.06)	1.000	0.02	(−0.03, 0.06)	0.472	(−0.04, 0.07)	0.752	−0.02	(−0.07, 0.03)	0.501	(−0.08, 0.04)	0.779
Triacylglycerols (mmol/l)[a]	−0.09	(−0.20, 0.03)	0.159	(−0.23, 0.06)	0.335	−0.11	(−0.23, 0.01)	0.064	(−0.25, 0.03)	0.153	0.03	(−0.10, 0.15)	0.678	(−0.12, 0.17)	0.909
Total cholesterol:HDL-c ratio[a]	−0.06	(−0.13, 0.01)	0.080	(−0.14, 0.02)	0.186	−0.05	(−0.12, 0.02)	0.127	(−0.14, 0.03)	0.277	−0.01	(−0.08, 0.06)	0.825	(−0.09, 0.08)	0.973
LDL-c:HDL-c ratio[a]	−0.09	(−0.19, 0.01)	0.084	(−0.21, 0.03)	0.195	−0.05	(−0.15, 0.05)	0.334	(−0.17, 0.07)	0.598	−0.04	(−0.15, 0.07)	0.460	(−0.17, 0.09)	0.740
Non-HDL-c (mmol/l)[a]	−0.09	(−0.17, −0.01)	0.026	(−0.19, 0.005)	0.067	−0.06	(−0.14, 0.02)	0.114	(−0.16, 0.03)	0.253	−0.03	(−0.11, 0.06)	0.526	(−0.13, 0.07)	0.801
Triacylglycerol:HDL-c ratio[a]	−0.08	(−0.22, 0.06)	0.238	(−0.25, 0.08)	0.464	−0.12	(−0.26, 0.02)	0.085	(−0.29, 0.04)	0.197	0.04	(−0.11, 0.18)	0.607	(−0.14, 0.21)	0.864
ApoA1 (g/l)	−0.03	(−0.08, 0.01)	0.131	(−0.09, 0.02)	0.286	−0.02	(−0.07, 0.02)	0.328	(−0.08, 0.03)	0.590	−0.01	(−0.06, 0.03)	0.604	(−0.07, 0.04)	0.862
ApoB (g/l)[a]	−0.09	(−0.16, −0.02)	0.015	(−0.17, −0.003)	0.039	−0.05	(−0.12, 0.02)	0.176	(−0.13, 0.04)	0.364	−0.04	(−0.11, 0.03)	0.290	(−0.13, 0.05)	0.540
ApoB:ApoA1[a]	−0.06	(−0.14, 0.01)	0.096	(−0.16, 0.03)	0.218	−0.01	(−0.08, 0.07)	0.850	(−0.10, 0.08)	0.981	−0.06	(−0.14, 0.02)	0.155	(−0.15, 0.04)	0.328
Serum CRP (nmol/l)[a]	0.00	(−0.36, 0.36)	0.996	(−0.43, 0.43)	1.000	−0.17	(−0.52, 0.19)	0.359	(−0.59, 0.26)	0.628	0.17	(−0.20, 0.54)	0.375	(−0.28, 0.61)	0.648
Fibrinogen (μmol/l)[a,c,d]	0.04	(−0.04, 0.12)	0.330	(−0.06, 0.13)	0.592	−0.02	(−0.10, 0.06)	0.648	(−0.11, 0.08)	0.891	0.06	(−0.02, 0.14)	0.169	(−0.04, 0.16)	0.352
Factor VII (U/ml)[c,d]	−0.06	(−0.12, −0.002)	0.043	(−0.13, 0.01)	0.106	−0.01	(−0.07, 0.05)	0.715	(−0.08, 0.06)	0.929	−0.05	(−0.11, 0.01)	0.110	(−0.12, 0.02)	0.244
Factor VIII (U/ml)[c,d]	0.02	(−0.08, 0.13)	0.662	(−0.10, 0.15)	0.900	0.01	(−0.10, 0.11)	0.878	(−0.12, 0.13)	0.987	0.01	(−0.09, 0.12)	0.786	(−0.11, 0.14)	0.960
PAI-1 (pmol/l)[c,d]	−45.1	(−178, 87.7)	0.502	(−204, 114)	0.779	−147	(−281, −13.1)	0.032	(−308, 13.6)	0.080	102	(−35.9, 240)	0.145	(−63.4, 268)	0.311
Systolic blood pressure (mmHg)	−0.03	(−3.96, 3.90)	0.990	(−4.73, 4.68)	1.000	−2.84	(−6.75, 1.06)	0.153	(−7.52, 1.83)	0.325	2.82	(−1.27, 6.90)	0.176	(−2.07, 7.70)	0.364
Diastolic blood pressure (mmHg)	−0.68	(−3.05, 1.69)	0.572	(−3.52, 2.16)	0.839	−1.41	(−3.77, 0.95)	0.240	(−4.23, 1.41)	0.467	0.73	(−1.73, 3.19)	0.560	(−2.22, 3.68)	0.829
Weight (kg)[c,e]	−0.33	(−1.11, 0.45)	0.407	(−1.26, 0.61)	0.683	−0.73	(−1.52, 0.06)	0.070	(−1.67, 0.22)	0.164	0.40	(−0.41, 1.21)	0.330	(−0.57, 1.37)	0.592
BMI (kg/m^2)[c,e]	−0.12	(−0.40, 0.16)	0.391	(−0.45, 0.21)	0.666	−0.26	(−0.54, 0.02)	0.070	(−0.59, 0.08)	0.164	0.14	(−0.15, 0.42)	0.343	(−0.21, 0.48)	0.609

Table 3 (continued)

	Full-dose nut vs full-dose muffin diet					Full-dose nut vs half-dose nut diet					Half-dose nut vs full-dose muffin diet				
	β	95% CI	*p*	Adj CI	Adj *p*	β	95% CI	*p*	Adj CI	Adj *p*	β	95% CI	*p*	Adj CI	Adj *p*
Waist (cm)[a,c,e]	0	(−0.03, 0.02)	0.738	(−0.04, 0.03)	0.940	0	(−0.03, 0.02)	0.821	(−0.04. 0.03)	0.972	0	(−0.03, 0.02)	0.917	(−0.03, 0.03)	0.994
Hip (cm)[c,e]	1	(−1, 2)	0.241	(−1, 2)	0.467	0	(−1, 2)	0.721	(−1, 2)	0.932	1	(−1, 2)	0.421	(−1, 2)	0.699
Waist/hip ratio[a,c,e]	−0.01	(−0.03, 0.01)	0.315	(−0.03, 0.01)	0.573	0	(−0.02, 0.02)	0.726	(−0.03, 0.02)	0.934	−0.01	(−0.03, 0.01)	0.519	(−0.03, 0.02)	0.794
Protein thiols (μmol/l)[c,f]	0.42	(−31.2, 32.1)	0.979	(−37.6, 38.4)	1.000	13.0	(−18.7, 44.8)	0.417	(−25.0, 51.1)	0.695	−12.6	(−45.6, 20.4)	0.449	(−52.2, 26.9)	0.728
Conjugated dienes (μmol/l)[a,c,e]	0.09	(−0.07, 0.25)	0.262	(−0.10, 0.28)	0.499	−0.05	(−0.21, 0.11)	0.513	(−0.25, 0.14)	0.789	0.14	(−0.02, 0.31)	0.088	(−0.06, 0.34)	0.202
TBARS (μmol/l)[a,c,e]	0.09	(−0.06, 0.23)	0.247	(−0.09, 0.26)	0.477	0.01	(−0.13, 0.16)	0.865	(−0.16, 0.19)	0.984	0.07	(−0.08, 0.23)	0.339	(−0.11, 0.26)	0.603

Unless otherwise indicated, $n = 108/117$; nine participants (half-dose nut group, $n = 5$; full- dose muffin group, $n = 4$) without post-intervention data are not captured in this analysis

Unless otherwise indicated, the outcome reported is change, modelled as change from baseline. Estimates taken from a repeated measures model in PROC MIXED, SAS 9.4, with sex, binary HbA_{1c} and lipid medications as covariates. Estimated from week 12 using least squares means with Tukey adjusted *p* values and confidence limits from all available data (week 2, 4, 8, 10 and 12)

[a] Data for which residuals were not normally distributed have been $\log_e$ transformed

[b] No covariates (without sex, binary HbA_{1c} or lipid medications as covariates). Values represent change from baseline, with estimates taken from a repeated measures model in PROC MIXED, SAS 9.4 (as above)

[c] *p* values taken from ANCOVA models; estimates taken from week 12 as change from baseline, outcome model against treatment with sex, binary HbA_{1c} and lipid medication as covariates. Tukey adjustment was applied for pairwise comparisons between the three treatment groups

[d] $n = 103$ (full-dose nut group, $n = 39$; half-dose nut group, $n = 32$; full-dose muffin group, $n = 32$)

[e] $n = 100$ (full-dose nut group, $n = 38$; half-dose nut group, $n = 32$; full-dose muffin group, $n = 30$)

[f] $n = 99$ (full-dose nut group, $n = 38$; half-dose nut group, $n = 31$; full-dose muffin group, $n = 30$); loss of $n = 1$ data point due to analytical failure for one participant in the half-dose nut group

Adj, adjusted; TBARS, thiobarbituric acid reactive substances